Wei L, et al. - Authors assessed the safety and efficacy of sofosbuvir + ribavirin ± peginterferon in Chinese patients infected with hepatitis C virus (HCV) genotype 1, 2, 3, or 6. For this study, subjects with genotype 1 or 6 received sofosbuvir + peginterferon/ribavirin for 12 weeks or sofosbuvir + ribavirin for 24 weeks, depending on prior treatment and interferon eligibility, while subjects with genotype 2 or 3 received sofosbuvir + ribavirin for 12 or 24 weeks, respectively. The inference drawn was that sofosbuvir-based regimens were highly effective and safe in Chinese patients with HCV genotype 1, 2, 3, or 6, which suggests that sofosbuvir could serve as the backbone for HCV treatment in China, regardless of genotype.